NYSE:IQV - Iqvia Stock Price, Forecast & News

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) issued its earnings results on Wednesday, October, 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.57 by $0.03. The medical research company had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.76 billion. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. Iqvia's revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the company posted $1.42 earnings per share. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Iqvia.

Iqvia issued an update on its fourth quarter earnings guidance on Wednesday, October, 30th. The company provided earnings per share guidance of $1.65-1.75 for the period, compared to the Thomson Reuters consensus estimate of $1.75. The company issued revenue guidance of $2.807-2.857 billion, compared to the consensus revenue estimate of $2.89 billion.

18 Wall Street analysts have issued 1-year target prices for Iqvia's stock. Their forecasts range from $136.38 to $185.00. On average, they anticipate Iqvia's stock price to reach $167.83 in the next twelve months. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

News coverage about IQV stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a news impact score of 2.9 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Iqvia.

Iqvia saw a decline in short interest during the month of December. As of December 13th, there was short interest totalling 3,280,000 shares, a decline of 7.6% from the November 28th total of 3,550,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is currently 2.4 days. Currently, 1.9% of the company's shares are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), Allergan (AGN), Alibaba Group (BABA), Athabasca Oil (ATH), Paypal (PYPL) and Accenture (ACN).

Iqvia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.32%), Arvest Bank Trust Division (0.11%), Artemis Investment Management LLP (0.07%), Howard Capital Management (0.06%), DNB Asset Management AS (0.06%) and McGuire Investment Group LLC (0.05%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, First Hawaiian Bank, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue, Howard Capital Management, Arvest Bank Trust Division, Legacy Capital Partners Inc. and Winslow Evans & Crocker Inc.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Nisa Investment Advisors LLC, McGuire Investment Group LLC, DNB Asset Management AS, Three Peaks Capital Management LLC, IFM Investors Pty Ltd, FTB Advisors Inc. and Appleton Partners Inc. MA. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $161.51.

Iqvia has a market capitalization of $31.34 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]